{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:44:58Z","timestamp":1793213098021,"version":"4.5.0"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL), a highly heterogeneous B-cell malignancy, is characterized by tumor microenvironment disorder and T-cell immune dysfunction, which play a major role in the proliferation and survival of CLL cells. Ibrutinib is the first irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK). In addition to targeting B-cell receptor (BCR) signaling to kill tumor cells, increasing evidence has suggested that ibrutinib regulates the tumor microenvironment and T-cell immunity in a direct and indirect manner. For example, ibrutinib not only reverses the tumor microenvironment by blocking cytokine networks and toll-like receptor signaling but also regulates T cells in number, subset distribution, T-cell receptor (TCR) repertoire and immune function by inhibiting interleukin-2 inducible T-cell kinase (ITK) and reducing the expression of inhibitory receptors, and so on. In this review, we summarize the current evidence for the effects of ibrutinib on the tumor microenvironment and cellular immunity of patients with CLL, particularly for the behavior and function of T cells, explore its potential mechanisms, and provide a basis for the clinical benefits of long-term ibrutinib treatment and combined therapy based on T-cell-based immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.962552","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:15:01Z","timestamp":1660896901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.6004\/jnccn.2020.0006","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4. 2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.3324\/haematol.2018.196543","article-title":"Immune failure, infection and survival in chronic lymphocytic leukemia","volume":"103","author":"Crassini","year":"2018","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.trecan.2018.01.004","article-title":"Resistance to ibrutinib in b cell malignancies: one size does not fit all","volume":"4","author":"Shah","year":"2018","journal-title":"Trends Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-Cells in chronic lymphocytic leukemia: Guardians or drivers of disease","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612244","article-title":"T Cells in chronic lymphocytic leukemia: a two-edged sword","volume":"11","author":"Vlachonikola","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in b-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-function relationships of covalent and non-covalent BTK inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771","article-title":"The role of bruton's kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment- na\u00efve chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1198-z","article-title":"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia","volume":"569","author":"Gaiti","year":"2019","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89904","article-title":"Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib","volume":"2","author":"Burger","year":"2017","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","article-title":"Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL","volume":"11","author":"Rendeiro","year":"2020","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133255","article-title":"T Cell defects and immunotherapy in chronic lymphocytic leukemia","volume":"13","author":"Vlachonikola","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2019-125417","article-title":"Ibrutinib treatment in CLL patients improves T cell function and blinatumomab redirected cytotoxicity","volume":"134","author":"Long","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.11","article-title":"Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood","volume":"31","author":"Herndon","year":"2017","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature b-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other b cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in b-cell chronic lymphocytic leukemia","volume":"110","author":"B\u00fcrkle","year":"2007","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01422","article-title":"Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles","volume":"10","author":"Dubois","year":"2020","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurse like cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and b-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment","volume":"1863","author":"Ten Hacken","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200205)32:5<1403::Aid-immu1403>3.0.Co;2-y","article-title":"Chronic lymphocytic leukemia b cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22","volume":"32","author":"Ghia","year":"2002","journal-title":"Eur J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16386","article-title":"Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis","volume":"189","author":"Delvecchio","year":"2020","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0057-5","article-title":"Toll-like receptors in the pathogenesis of human b cell malignancies","volume":"7","author":"Isaza-Correa","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0781","article-title":"TLR signaling is activated in lymph node-resident CLL cells and is only partially inhibited by ibrutinib","volume":"79","author":"Dadashian","year":"2019","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013926","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroy","year":"2022","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.326.326","article-title":"Functional evidence from deuterated water labeling that the bruton tyrosine kinase inhibitor ibrutinib blocks leukemia cell proliferation and trafficking and promotes leukemia cell death in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"124","author":"Burger","year":"2014","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in b cell chronic lymphocytic leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"Herman","year":"2014","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000564","article-title":"Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia","volume":"5","author":"Mulder","year":"2021","journal-title":"Hemasphere"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T Cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"ra122","DOI":"10.1126\/scisignal.aab0949","article-title":"Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response","volume":"8","author":"Sun","year":"2015","journal-title":"Sci Signal"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","article-title":"Restoration of the immune function as a complementary strategy to treat chronic lymphocytic leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637186","article-title":"Th2\/Th1 shift under ibrutinib treatment in chronic lymphocytic leukemia","volume":"11","author":"Puzzolo","year":"2021","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100","article-title":"T Cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(01)00194-1","article-title":"T Type 1\/type 2 subsets balance in b-cell chronic lymphocytic leukemia\u2013the three-color flow cytometry analysis","volume":"26","author":"Podhorecka","year":"2002","journal-title":"Leuk Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.immuni.2004.06.009","article-title":"Signaling through ITK promotes T helper 2 differentiation via negative regulation of T-bet","volume":"21","author":"Miller","year":"2004","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457147","article-title":"Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia","volume":"59","author":"Pleyer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.298","article-title":"The skewed balance between tregs and Th17 in chronic lymphocytic leukemia","volume":"11","author":"Yousefi","year":"2015","journal-title":"Future Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048992","article-title":"Regulatory T cell targeting in cancer: emerging strategies in immunotherapy","volume":"51","author":"Dees","year":"2021","journal-title":"Eur J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078091","article-title":"Th17\/IL-17A might play a protective role in chronic lymphocytic leukemia immunity","volume":"8","author":"Hus","year":"2013","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.781364","article-title":"A specific CD44lo CD25lo subpopulation of regulatory T cells inhibits anti-leukemic immune response and promotes the progression in a mouse model of chronic lymphocytic leukemia","volume":"13","author":"Goral","year":"2022","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumour Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2017.07.004","article-title":"Quantitative and qualitative analysis of regulatory T cells in b cell chronic lymphocytic leukemia","volume":"60","author":"Mpakou","year":"2017","journal-title":"Leuk Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1330475","article-title":"Regulatory T-cells drive immune dysfunction in CLL","volume":"59","author":"Lad","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28884","article-title":"Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia","volume":"135","author":"Rissiek","year":"2014","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16148","article-title":"Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number","volume":"8","author":"Podhorecka","year":"2017","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10875-019-00632-5","article-title":"Genetic deficiency and biochemical inhibition of ITK affect human Th17, treg, and innate lymphoid cells","volume":"39","author":"Eken","year":"2019","journal-title":"J Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026740","article-title":"Coevolution of leukemia and host immune cells in chronic lymphocytic leukemia","volume":"7","author":"Purroy","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3324\/haematol.2011.047316","article-title":"Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance","volume":"97","author":"Jain","year":"2012","journal-title":"Haematologica"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986479","article-title":"Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias","volume":"56","author":"Lad","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158243","article-title":"Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners","volume":"7","author":"Jung","year":"2022","journal-title":"JCI Insight"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1042\/BST20190486","article-title":"Tuning T helper cell differentiation by ITK","volume":"48","author":"Elmore","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343751","article-title":"The who's who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T Cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00929","article-title":"Molecular determinants of target cell recognition by human gammadelta T cells","volume":"9","author":"Simoes","year":"2018","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040661","article-title":"The mysterious actor-gammadelta T lymphocytes in chronic lymphocytic leukaemia (CLL)","volume":"11","author":"Zarobkiewicz","year":"2022","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL Vgamma9Vdelta2-t-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-876078","article-title":"Gammadelta T cells for immunotherapy","volume":"132","author":"Long","year":"2018","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000924","article-title":"Natural killer-like T CD3+\/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome","volume":"24","author":"Bojarska-Junak","year":"2010","journal-title":"Oncol Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751065","article-title":"Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis","volume":"129","author":"Gorini","year":"2017","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071582","article-title":"Mucosal associated invariant T cells in cancer-friend or foe","volume":"13","author":"O'Neill","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.intimp.2015.03.047","article-title":"An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia","volume":"28","author":"Wallace","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16260","article-title":"Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL","volume":"188","author":"Elston","year":"2020","journal-title":"Br J Haematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019","volume":"7","author":"Lemal","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15918","article-title":"Chronic lymphocytic leukaemia: the role of T cells in a b cell disease","volume":"186","author":"Man","year":"2019","journal-title":"Br J Haematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","article-title":"T Cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1172\/jci35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3827","article-title":"T-Cell dynamics in chronic lymphocytic leukemia under different treatment modalities","volume":"26","author":"Vardi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood-2018-99-118333","article-title":"Ibrutinib-based therapy improves anti-tumor T cell killing function allowing effective pairing with anti-PD-L1 immunotherapy compared to traditional FCR chemoimmunotherapy; implications for therapy and correlative immune functional data from the phase III E1912 trial","volume":"132","author":"Papazoglou","year":"2018","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-020-00253-w","article-title":"Longitudinal CITE-seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse","volume":"8","author":"Cadot","year":"2020","journal-title":"biomark Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in em-TCL1 mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica"},{"key":"B103","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2018-99-109847","article-title":"Ibrutinib increases the clonality of TCR repertoire in patients with chronic lymphocytic leukemia","volume":"132","author":"Baptista","year":"2018","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0746","article-title":"Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with b-cell chronic lymphocytic leukemia","volume":"101","author":"Rezvany","year":"2003","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-3017","article-title":"Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia","volume":"22","author":"Vardi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.362","article-title":"Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements","volume":"31","author":"Vardi","year":"2017","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1432328","article-title":"Restricted T cell receptor repertoire in CLL-like monoclonal b cell lymphocytosis and early stage CLL","volume":"7","author":"Blanco","year":"2018","journal-title":"Oncoimmunology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3978\/j.issn.2306-9759.2015.09.01","article-title":"Evaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation","volume":"2","author":"Li","year":"2015","journal-title":"Stem Cell Investig"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.267914","article-title":"T-Cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4140.4140","article-title":"Ibrutinib potentiated NK cell-mediated cytotoxicity in mouse models of b-cell lymphomas","volume":"128","author":"Kuo","year":"2016","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140491","article-title":"Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients","volume":"136","author":"Siddiqi","year":"2020","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005362","article-title":"CAR-T and ibrutinib vs CLL: sequential or simultaneous","volume":"135","author":"Kater","year":"2020","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int J Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nri3442","article-title":"The integration of T cell migration, differentiation and function","volume":"13","author":"Masopust","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in b-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.962552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:15:06Z","timestamp":1660896906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.962552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":128,"alternative-id":["10.3389\/fimmu.2022.962552"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.962552","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"article-number":"962552"}}